Announcements Trials
Browse Landscape

Phase

Phase 3 7Phase 1 5Phase 2 4Phase NA 2Phase 4 2Phase 2/3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 6Endometrial Neoplasms 4Progesterone Resistance 2Polycystic Ovary Syndrome 2Endometrial Hyperplasia 2Uterine Neoplasms 1Obesity 1Neoplasm Metastasis 1Inflammatory Breast Neoplasms 1Infertility 1Hydatidiform Mole 1Hormone Receptor Positive HER-2 Negative Breast Cancer 1Gestational Trophoblastic Disease 1Cystadenocarcinoma, Serous 1Carcinoma, Ductal, Breast 1Breast Diseases 1

Interventions

Gemcitabine 5Capecitabine 4pembrolizumab 3Fluorouracil 3Cisplatin 3vinflunine 2enzalutamide 2cabazitaxel 2abiraterone 2Ipilimumab 2Haloperidol 2Androgen Antagonists 2vedolizumab 1trifluridine tipiracil drug combination 1relugolix 1racemetyrosine 1nimotuzumab 1nilutamide 1lanreotide 1histrelin 1futibatinib 1exemestane 1dexamethasone acetate 1dexamethasone 21-phosphate 1bicalutamide 1beta-Glucans 1auricularum 1atezolizumab 1apatinib 1apalutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Neoplasm Metastasis × Letrozole × Clear all
NCT00684216 2017-09-14

Second-line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast Cancer

The Netherlands Cancer Institute

Phase 2/3 Terminated
10 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡